ストックスクリーナーアプリを入手
1.0979
3.69%
-0.0421
前日終値:
$1.14
開ける：
$1.12
24時間の取引高:
183.00K
Relative Volume:
0.67
時価総額：
$4.77M
収益：
$79,300
当期純損益:
$-6.92M
株価収益率:
-0.0578
EPS:
-18.9818
ネットキャッシュフロー:
$-5.34M
1週間 パフォーマンス:
-14.89%
1か月 パフォーマンス:
-34.26%
6か月 パフォーマンス:
-32.23%
1年 パフォーマンス:
+49.37%
1日の値動き範囲:
$1.07
$1.1363
1週間の範囲:
$1.07
$1.35
52週間の値動き範囲:
$0.60
$8.9999
Virax Biolabs Group Ltd Stock (VRAX) Company Profile
VRAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRAX
Virax Biolabs Group Ltd
|
1.0979 | 4.77M | 79,300 | -6.92M | -5.34M | -18.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Virax Biolabs Group Ltd Stock (VRAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-31 | 開始されました | H.C. Wainwright | Buy |
Virax Biolabs Group Ltd (VRAX) 最新ニュース
Virax Biolabs Group (NASDAQ:VRAX) Coverage Initiated by Analysts at HC Wainwright - Defense World
Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating - Benzinga
Virax Biolabs Group Ltd.’s Innovative Diagnostics and Strategic Collaborations Justify Buy Rating - TipRanks
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update - Defense World
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Down 3.9% – What’s Next? - Defense World
Virax Biolabs Launches Clinical Study on T Cell Dysfunction - TipRanks
Virax Biolabs begins UK clinical study on T cell dysfunction - Investing.com India
Breakthrough T Cell Study: Virax Targets Long COVID and Chronic Fatigue Diagnosis Revolution - StockTitan
Virax Biolabs Highlights T-Cell Dysfunction in Post-Infection Syndromes - TipRanks
Virax Biolabs shares T-Cell dysfunction findings - Investing.com India
Virax Biolabs shares T-Cell dysfunction findings By Investing.com - Investing.com South Africa
Game-Changing Long COVID Diagnostic: Virax's New T-Cell Test Shows Promising Results - StockTitan
Virax Biolabs to Present at World Immune Regulation Meeting - TipRanks
Can Virax's T-Cell Research at WIRM 2025 Advance Post-Infection Syndrome Treatment? - StockTitan
Cosmos Health expands distribution of Avian Influenza kits - MSN
Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Expands By 205.8% - Defense World
Virax Biolabs aligns with US vaccine transparency efforts By Investing.com - Investing.com South Africa
Virax Biolabs Aligns with US Health Department on Vaccine Transparency - TipRanks
How Virax's Vaccine Testing Tech Could Capitalize on New Government Transparency Push - StockTitan
EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency - Benzinga
Contrasting Virax Biolabs Group (NASDAQ:VRAX) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Market Watch: Virax Biolabs Group Ltd (VRAX)’s Noteworthy Drop, Closing at 1.71 - The Dwinnex
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 33.9% in January - Armenian Reporter
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait - Yahoo Finance
Cosmos Health secures exclusive distribution agreement with Virax Biolabs - Yahoo Finance
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries - Lelezard
Virax Biolabs Group Ltd (VRAX) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know - MSN
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 38.5% in December - Defense World
Virax Biolabs Achieves Shareholder Approvals at Adjourned Annual Meeting - TipRanks
Stock Region Signal Report - substack.com
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Virax Biolabs Announces Strategic Goals and Developments for 2025 - TipRanks
Virax Biolabs Advances T-Cell Platform with $7.3M War Chest, Expands European Distribution Network - StockTitan
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect across the European Union, Norway, and Switzerland - Marketscreener.com
Virax Biolabs Expands ImmuneSelect Reach in Europe - TipRanks
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland - Yahoo Finance
Virax Biolabs Group First Half 2025 Earnings: US$0.89 loss per share (vs US$1.64 loss in 1H 2024) - Simply Wall St
Virax Biolabs Sees Asset Growth Amid Financial Loss - TipRanks
ARMISTICE CAPITAL, LLC Acquires New Stake in Virax Biolabs Group Ltd - GuruFocus.com
Virax Biolabs announces 2024 annual meeting - Investing.com India
Virax Biolabs announces 2024 annual meeting By Investing.com - Investing.com UK
Virax Biolabs Sets Date for 2024 AGM - TipRanks
Virax Biolabs announces distribution agreement with Europa Biosite - TipRanks
Virax Biolabs Expands Reach with Europa Biosite Deal - TipRanks
EXCLUSIVE: Virax Biolabs Inks Distribution Pact To Commercialize ImmuneSelect Profiling Solutions In UK And Ireland - Yahoo Finance
Virax Biolabs Group Ltd (VRAX) 財務データ
収益
当期純利益
現金流量
EPS
3.89%
0.13%
大文字化:
|
ボリューム (24 時間):